Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMSA101 Rollover Study for Advanced Malignancies
NCT06026254Phase 1Active, not recruiting
- Sponsor
- ImmuneSensor Therapeutics
- Start
- Sep 2023
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IMSA101 in solid tumor, sponsored by ImmuneSensor Therapeutics. Primary endpoints: Drug-related safety at 12 months and Anti-tumor effects at 12 months. Started Sep 2023; status: active, not recruiting.
02
Drugs
IMSA101
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06026254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06026254.